Cargando…
Cost-effectiveness analysis of sarcopenia management interventions in Iran
OBJECTIVES: Identification the optimal management intervention of sarcopenia is a concern of health systems. We aimed to analyze the cost-effectiveness of sarcopenia management strategies in Iran. METHODS: We constructed a lifetime Markov model based on natural history. The strategies comparedinclud...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157910/ https://www.ncbi.nlm.nih.gov/pubmed/37143011 http://dx.doi.org/10.1186/s12889-023-15693-w |
_version_ | 1785036852649000960 |
---|---|
author | Darvishi, Ali Shafiee, Gita Balajam, Narges Zargar Hemami, Mohsen Rezaei Ostovar, Navid Heshmat, Ramin |
author_facet | Darvishi, Ali Shafiee, Gita Balajam, Narges Zargar Hemami, Mohsen Rezaei Ostovar, Navid Heshmat, Ramin |
author_sort | Darvishi, Ali |
collection | PubMed |
description | OBJECTIVES: Identification the optimal management intervention of sarcopenia is a concern of health systems. We aimed to analyze the cost-effectiveness of sarcopenia management strategies in Iran. METHODS: We constructed a lifetime Markov model based on natural history. The strategies comparedincluded exercise training, nutritional supplements, whole body vibration (WBV), and various exercise interventions and nutritional supplement combinations. A total of 7 strategies was evaluated in addition to the non-intervention strategy. Parameter values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Deterministic and probabilistic sensitivity analysis, including the expected value of perfect information (EVPI), was also performed to determine the robustness of the model. Analyses were performed using the 2020 version of TreeAge Pro software. RESULTS: All seven strategies increased lifetime effectiveness (QALYs). The protein and Vitamin D(3) (P + D) strategy had the highest effectiveness values among all strategies. After removing the dominated strategies, the estimated ICER for the P + D compared to Vitamin D(3) alone (D) strategy was calculated as $131,229. Considering the cost-effectiveness threshold ($25,249), base-case results indicated that the D strategy was the most cost-effective strategy in this evaluation. Sensitivity analysis of model parameters also demonstrated the robustness of results. Also, EVPI was estimated at $273. CONCLUSIONS: Study results, as the first economic evaluation of sarcopenia management interventions, showed that despite the higher effectiveness of D + P, the D strategy was the most cost-effective. Completing clinical evidence of various intervention options can lead to more accurate results in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-023-15693-w. |
format | Online Article Text |
id | pubmed-10157910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101579102023-05-05 Cost-effectiveness analysis of sarcopenia management interventions in Iran Darvishi, Ali Shafiee, Gita Balajam, Narges Zargar Hemami, Mohsen Rezaei Ostovar, Navid Heshmat, Ramin BMC Public Health Research OBJECTIVES: Identification the optimal management intervention of sarcopenia is a concern of health systems. We aimed to analyze the cost-effectiveness of sarcopenia management strategies in Iran. METHODS: We constructed a lifetime Markov model based on natural history. The strategies comparedincluded exercise training, nutritional supplements, whole body vibration (WBV), and various exercise interventions and nutritional supplement combinations. A total of 7 strategies was evaluated in addition to the non-intervention strategy. Parameter values were extracted from primary data and the literature, and the costs and Quality-adjusted life years (QALYs) were calculated for each strategy. Deterministic and probabilistic sensitivity analysis, including the expected value of perfect information (EVPI), was also performed to determine the robustness of the model. Analyses were performed using the 2020 version of TreeAge Pro software. RESULTS: All seven strategies increased lifetime effectiveness (QALYs). The protein and Vitamin D(3) (P + D) strategy had the highest effectiveness values among all strategies. After removing the dominated strategies, the estimated ICER for the P + D compared to Vitamin D(3) alone (D) strategy was calculated as $131,229. Considering the cost-effectiveness threshold ($25,249), base-case results indicated that the D strategy was the most cost-effective strategy in this evaluation. Sensitivity analysis of model parameters also demonstrated the robustness of results. Also, EVPI was estimated at $273. CONCLUSIONS: Study results, as the first economic evaluation of sarcopenia management interventions, showed that despite the higher effectiveness of D + P, the D strategy was the most cost-effective. Completing clinical evidence of various intervention options can lead to more accurate results in the future. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-023-15693-w. BioMed Central 2023-05-04 /pmc/articles/PMC10157910/ /pubmed/37143011 http://dx.doi.org/10.1186/s12889-023-15693-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Darvishi, Ali Shafiee, Gita Balajam, Narges Zargar Hemami, Mohsen Rezaei Ostovar, Navid Heshmat, Ramin Cost-effectiveness analysis of sarcopenia management interventions in Iran |
title | Cost-effectiveness analysis of sarcopenia management interventions in Iran |
title_full | Cost-effectiveness analysis of sarcopenia management interventions in Iran |
title_fullStr | Cost-effectiveness analysis of sarcopenia management interventions in Iran |
title_full_unstemmed | Cost-effectiveness analysis of sarcopenia management interventions in Iran |
title_short | Cost-effectiveness analysis of sarcopenia management interventions in Iran |
title_sort | cost-effectiveness analysis of sarcopenia management interventions in iran |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157910/ https://www.ncbi.nlm.nih.gov/pubmed/37143011 http://dx.doi.org/10.1186/s12889-023-15693-w |
work_keys_str_mv | AT darvishiali costeffectivenessanalysisofsarcopeniamanagementinterventionsiniran AT shafieegita costeffectivenessanalysisofsarcopeniamanagementinterventionsiniran AT balajamnargeszargar costeffectivenessanalysisofsarcopeniamanagementinterventionsiniran AT hemamimohsenrezaei costeffectivenessanalysisofsarcopeniamanagementinterventionsiniran AT ostovarnavid costeffectivenessanalysisofsarcopeniamanagementinterventionsiniran AT heshmatramin costeffectivenessanalysisofsarcopeniamanagementinterventionsiniran |